Skip to content

Insider · CIK 0001768011

Katharine Knobil

director

Files at MRKR (Marker Therapeutics, Inc.), KRRO (Korro Bio, Inc.), PLRX (PLIANT THERAPEUTICS, INC.). First filing -, latest -.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jun 11, 2025KRRO
Korro Bio, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+6,010$0.00$06,010Jun 12, 2025
Jun 5, 2025PLRX
PLIANT THERAPEUTICS, INC.
AGrant or award
Common Stock (Right to Buy)derivative
+30,000$0.00$030,000Jun 9, 2025
Feb 12, 2025MRKR
Marker Therapeutics, Inc.
AGrant or award
Stock Option (right to buy)derivative
+30,000$0.00$030,000Feb 14, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Katharine Knobil: insider trades and track record | InsiderTell